Individuals with memory problems encouraged to learn more about study
We’re excited to open this trial in Houston to study ACU193 for the treatment of Alzheimer’s disease.”
— Dr. Berrios
HOUSTON, TEXAS, UNITED STATES, September 14, 2022 /EINPresswire.com/ -- Clinical Trial Network is initiating a clinical trial for a promising new investigational treatment for Alzheimer’s disease (AD) in Houston.
The Phase I study will determine the safety and tolerability of a single intravenous (IV) dose and multiple IV doses of ACU193. We are asking individuals who have memory problems to consider participating in the trial to assist in evaluating this medication for the treatment of Alzheimer’s disease. There is no cost to participate. Acumen Pharmaceuticals Inc., a clinical stage biopharmaceutical company focused on the development of novel targeted therapeutics for AD, is sponsoring the clinical trial.
ACU193 targets amyloid-beta oligomers and is a different approach to treating Alzheimer’s disease than currently approved medications. ACU193 is designed to locate and bind to amyloid-beta oligomers – proteins that build up in the brain in people with Alzheimer’s disease. These proteins are thought to be involved in Alzheimer’s disease symptoms and progression.
The trial site, located at 7080 Southwest Fwy, Houston, TX 77074, is led by principal investigator Dr. Nelson Berrios, [TITLE] at Clinical Trial Network. Patients who believe they qualify for the study are asked to call [PHONE NUMBER] or email [EMAIL ADDRESS] to learn more.
“We’re excited to open this trial in Houston to study ACU193 for the treatment of Alzheimer’s disease,” Dr. Berrios said. “If you or a loved one is experie...